
ELV Stock Forecast & Price Target
ELV Analyst Ratings
Bulls say
Elevance Health is maintaining its strong position as a leader in the health insurance industry with its unique role as the largest single provider of Blue Cross Blue Shield branded coverage and its expansion into new markets through acquisitions. The company is also diversifying with growth opportunities in pharmacy benefit management and other healthcare services. Despite potential risks, such as Medicaid cost spikes and adverse selection, Elevance's careful capital deployment, strong balance sheet, and commitment to returning to >12% EPS growth in 2027+ make it an attractive investment opportunity with potential for continued margin expansion and increased profitability in the coming years.
Bears say
Elevance Health is facing several challenges in the upcoming years, including declining membership in Medicare Advantage and Medicaid plans, misalignment between rates and acuity, and potential market exits. These factors will likely result in pressure on margins and may hinder the company's ability to meet its 12% EPS growth target for 2027. The company's investments in AI/tech adoption and Carelon scalability may also create a significant SG&A headwind to EPS in the coming years. Additionally, the risk of unexpected ACA risk pool deterioration, Medicaid cost increases, an elongated turnaround for MA, and erratic pricing cycles could further impact the company's financial performance.
This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELV Analyst Forecast & Price Prediction
Start investing in ELV
Order type
Buy in
Order amount
Est. shares
0 shares